Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization  by Gajewski, James L et al.
550
INTRODUCTION
Peripheral blood progenitor cell (PBPC) transplantation
has made possible the widespread use of myeloablative cyto-
toxic therapy to treat chemotherapy-responsive malignan-
cies [1-6]. Recombinant hematopoietic growth factors,
including granulocyte colony-stimulating factor (G-CSF)
and granulocyte-macrophage (GM)-CSF, have been used
alone or with chemotherapy to mobilize PBPCs that can be
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ABSTRACT
This phase I/II dose-escalation study examined the safety and efficacy of recombinant human thrombopoietin
(rhTPO) and granulocyte colony-stimulating factor (G-CSF) for postchemotherapy mobilization of peripheral
blood progenitor cells (PBPCs) in patients with advanced breast cancer. Patients received cyclophosphamide, etopo-
side, and cisplatin (CVP) followed by G-CSF (6 µg/kg twice a day) and rhTPO (0.6, 1.2, 2.4, or 3.6 µg/kg as a single
dose on day 5 or as 3 doses on days 5, 7, and 9 after chemotherapy). PBPCs were collected by daily leukapheresis
when the postnadir white blood cell count reached ≥2 × 109/L; leukapheresis was continued until acquisition of a
target dose of ≥5 × 106 CD34+ cells/kg. Mobilized PBPCs were transplanted into patients after additional high-dose
chemotherapy with cyclophosphamide, carmustine, and thiotepa (CBT). Comparisons were made with contempora-
neously treated, nonrandomized, control patients who received the same chemotherapy regimens and G-CSF sup-
port but who did not receive rhTPO. Of 32 evaluable patients receiving rhTPO and G-CSF after CVP, 91%
required only 1 leukapheresis to achieve a target PBPC graft; by contrast, only 69% of 36 of the control patients
achieved the target graft with just 1 leukapheresis (P = .026). A median of 26.7 × 106 CD34+ cells/kg per leukaphere-
sis was obtained from the rhTPO-treated patients compared with 11.5 × 106 cells/kg per leukapheresis from the
controls (P = .09). Higher rhTPO doses appeared to yield more CD34+ cells. When PBPCs were infused after high-
dose CBT chemotherapy, the median times to return of an absolute neutrophil count of 0.5 × 109/L and a platelet
count of 20 × 109/L were 15 and 16 days, respectively; these values did not differ from those in the control group
(15 days for both neutrophil and platelets). No patient developed anti-TPO antibodies. These results indicate that
rhTPO safely and effectively augments the number of PBPCs mobilized with chemotherapy and G-CSF and can
reduce the required number of leukaphereses. Further studies are also warranted in patients who are likely to expe-
rience suboptimal PBPC mobilization when treated with currently available techniques.
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harvested by leukapheresis [7-9]. From 2 to 6 leukapheresis
sessions are often required to obtain a sufﬁcient number of
PBPCs (usually ≥2 × 106 CD34+ cells/kg) for rapid and
durable hematopoietic recovery [9]. In some patients,
PBPCs are difﬁcult to mobilize, particularly in patients who
have been heavily pretreated with chemotherapy or who
have had prior radiation therapy to marrow-bearing sites
[9]. Collection of an insufﬁcient number of CD34+ hemato-
poietic progenitors may render these patients ineligible for
high-dose chemotherapies requiring progenitor cell sup-
port. More effective treatment to mobilize hematopoietic
stem/progenitor cells is needed to reduce collection times
and enhance cell yields.
Thrombopoietin (TPO), the ligand for the cytokine
receptor c-mpl, is a naturally occurring glycosylated peptide
growth factor and the primary regulator of thrombopoiesis
[10-15]. Activation of c-mpl by TPO stimulates the differ-
entiation of megakaryocyte progenitors, promotes mega-
karyocyte proliferation and maturation, and increases
platelet production. TPO also acts synergistically with other
hematopoietic growth factors to enhance the differentiation
of primitive hematopoietic cells committed to the erythroid
and myelomonocytic lineages [16]. Recombinant human
thrombopoietin (rhTPO), a full-length glycosylated mole-
cule, is homologous to native TPO. In preclinical studies,
administration of TPO to normal mice caused a rapid 4- to
6-fold increase in circulating platelets and increased the
number and ploidy of bone marrow and splenic megakaryo-
cytes [12]. In murine models of myelosuppression, TPO
accelerated platelet recovery and ameliorated thrombocy-
topenia [17]. Similar results were noted in the ﬁrst human
trials in cancer patients; when administered alone or with
myelosuppressive and myeloablative cytotoxic chemo-
therapy, rhTPO safely stimulated thrombopoiesis [18-21],
and when administered with G-CSF or GM-CSF, rhTPO
enhanced PBPC mobilization [21,22].
PBPC mobilization can be enhanced when colony-
stimulating factors are administered after myelosuppressive
chemotherapy [9]; however, it has not been previously
demonstrated that addition of rhTPO to a regimen of
chemotherapy and G-CSF can improve mobilization effi-
ciency. This study was conducted to evaluate the safety and
PBPC-mobilizing activity of single and multiple doses of
rhTPO combined with G-CSF in patients with breast cancer
who were receiving chemotherapy for PBPC mobilization.
PATIENTS AND METHODS
Patients
Patients with a histologically confirmed diagnosis of
high-risk stage II/III or metastatic breast cancer were
enrolled in the study. Patients with metastatic disease were
required to have evidence that their cancer had responded
to standard-dose chemotherapy and to have minimal resid-
ual disease. Patients were also required to have an Eastern
Cooperative Oncology Group performance status of 0 or 1,
white blood cell count (WBC) ≥3.5 × 109/L, absolute neu-
trophil count (ANC) ≥1.5 × 109/L, platelet count ≥100 ×
109/L and ≤500 × 109/L, adequate liver function, left ven-
tricular cardiac ejection fraction ≥50%, and creatinine clear-
ance ≥60 mL/min.
Patients were excluded from the study if they had mor-
phologically identiﬁed bone marrow involvement with malig-
nancy, central nervous system metastases, a history of platelet
disorders, venous thromboembolism, or myocardial or central
nervous system ischemia within 6 months before study entry.
Patients could not have received more than 3 prior chemo-
therapy regimens. Patients were also excluded from study
participation if they had undergone prior treatment with mit-
omycin C or carmustine (BCNU), previous pelvic irradiation,
prior bone marrow or PBPC transplantation, or treatment
with chemotherapy or experimental drugs ≤4 weeks before
study entry.
To enhance the understanding of the influence of
rhTPO on PBPC mobilization efﬁcacy and posttransplanta-
tion hematologic recovery that could be gained by this
study, we identified a control group. The control group
comprised patients with stage II to III breast cancer who
were concurrently and identically treated on an institutional
protocol but who did not receive rhTPO. The rhTPO study
was episodically closed to patient accrual to allow time to
observe for toxicity endpoints. We had a trial running con-
currently so that all potential study patients were treated on
protocol. This study was opened 1 year prior to the rhTPO
study and was closed in 2002. The patients in the control
study were treated within 2 years of the rhTPO trial to
allow for similarities in supportive care. Flow cytometry
analyses in these patients were performed by the same labo-
ratory using the same gating as was employed in rhTPO-
treated patients.
All patients (including those treated in the control
group) were required to sign a written informed consent
document that had been approved by the institutional
review board.
Study Treatment
During the mobilization phase, patients received
cyclophosphamide, etoposide, and cisplatin (CVP) chemo-
therapy. The regimen comprised a single cycle of intra-
venous treatment with cyclophosphamide 1.5 g/m2 on days
1 to 3, etoposide 250 mg/m2 on days 1 to 4, and cisplatin
40 mg/m2 on days 1 to 3 [23]. As outlined in Table 1, cohorts
of 3 to 6 patients were sequentially assigned to receive pro-
gressively longer courses and higher doses of rhTPO (Phar-
macia, Peapack, NJ; Genentech, South San Francisco, CA)
by intravenous injection via central venous catheter. Patients
assigned to group A of the study received a single dose of
rhTPO at dose levels of 0.6, 1.2, 2.4, or 3.6 µg/kg on day 5
after CVP. Patients in group B were treated with rhTPO at
dose levels of 0.6, 1.2, 2.4, or 3.6 µg/kg on days 5, 7, and 9
after CVP. Patients in group C received 1.2 µg/kg of
rhTPO on days 5, 7, and 9 after CVP and on days –14, –11,
0, 2, 4, and 6 relative to high-dose chemotherapy and PBPC
infusion during the transplantation phase of the study. No
intrasubject dose escalation was allowed. In all groups, the
maximum tolerated rhTPO dose was deﬁned as 1 dose level
below that associated with 2 episodes of grade 3 toxicity or
an increase in platelet count to >600 × 109/L persisting
beyond 24 hours. G-CSF (Neupogen; Amgen, Thousand
Oaks, CA) 6 µg/kg was administered to all patients twice
daily (subcutaneously or intravenously) starting on day 5
after CVP chemotherapy and continuing until completion
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of leukapheresis. Patients were not to receive aspirin (except
when used to treat thrombosis), nonsteroidal antiinﬂamma-
tory agents, anticoagulants, or colony-stimulating factors
other than G-CSF.
Patients underwent large-volume leukapheresis (3 times
their calculated total blood volume) for PBPC collection
after the CVP nadir when the WBC reached ≥2 × 109/L.
PBPCs were collected daily for up to 5 days or until a target
cell dose of 5 × 106 CD34+ cells/kg was obtained. Pro-
grammed freezing was used to cryopreserve cells in 10%
dimethylsulfoxide. Patients with a minimum cumulative tar-
get dose of ≥2.0 × 106 CD34+ cells/kg were eligible to pro-
ceed to the transplantation phase of the study.
During the transplantation phase, patients received high-
dose intravenous chemotherapy consisting of cyclophos-
phamide 2 g/m2, BCNU 150 mg/m2, and thiotepa 240 mg/m2
(CBT); all drugs were given on days –7, –6, and –5. PBPCs
were infused 5 days after completion of CBT chemotherapy
(on day 0) [23]. G-CSF 5 µg/kg was administered (either
intravenously or subcutaneously) to patients in all study
groups daily starting 1 day after PBPC infusion and contin-
uing until ANC recovery to ≥5 × 109/L. Only patients in
group C received rhTPO 1.2 µg/kg on days –14, –11, 0, 2,
4, and 6 relative to CBT therapy and PBPC infusion.
Platelet transfusions were administered to all patients with
platelet counts of ≤20 × 109/L.
Clinical Patient Monitoring
Patients were monitored for adverse reactions after each
injection of rhTPO and at each visit. Total WBC, WBC dif-
ferential, and platelet counts were determined on the days of
rhTPO and G-CSF administration and before each leuka-
pheresis. Blood counts were monitored daily in the trans-
plantation phase. The serum chemistry profile, electrolyte
values, and coagulation parameters were monitored weekly
during the mobilization, transplantation, and follow-up
phases (on days 28, 35, 42, and 49).
Anti-TPO Antibody Screening
Blood samples were serially tested for the presence of
anti-TPO antibodies at the screening visit, before the ﬁrst
rhTPO administration, and weekly through day 49 of the
follow-up period. Initial screening was performed using an
enzyme-linked immunosorbent assay (ELISA) based on the
full-length TPO molecule. The assay reported results as
either positive or negative. For samples identiﬁed as positive
in the full length ELISA, the sample was titered in a similar
assay based on a truncated version of the molecule that
included the c-mpl binding domain. Such samples were also
evaluated in functional assays to determine if any potential
antibodies blocked TPO binding to the c-mpl receptor and
inhibited proliferation of the TPO-dependent HU-3 cell
line. For antibodies to be considered neutralizing, a positive
HU-3 bioassay result in the presence of persistent, clinically
signiﬁcant thrombocytopenia was required.
Statistical Analysis
Patient characteristics, treatment administration, and
potential rhTPO-related adverse events were assessed
descriptively. The t test was used to compare the total
number of CD34+ PBPCs mobilized in rhTPO-treated
patients and controls. The Wilcoxon signed-rank test was
similarly employed to assess the number of leukaphereses
required to obtain the target CD34+ cell dose. The number
of days required to reach an ANC >0.5 × 109/L and
platelet counts ≥20, 50, and 100 × 109/L were calculated.
Time from start of CVP therapy was calculated in the
mobilization phase, and time from PBPC infusion (day 0)
was determined in the transplantation phase. Kaplan-
Meier methods and the Tarone-Ware log-rank test were
used to compare time to hematologic recovery for all
rhTPO-treated patients and controls. The numbers of
platelet transfusions required were also tabulated. Statisti-
cal software Systat 8.0 (SPSS, Chicago, IL) was used for
statistical analysis.
Table 1. Baseline Patient Characteristics
rhTPO-Treated Patients
Group A* Group B† Group C‡ Control
rhTPO dose level, µg/kg 0.6 1.2 2.4 3.6 0.6 1.2 2.4 3.6 1.2 Overall Patients
Enrolled, n 4 3 3 3 5 3 3 3 6 33 37
Treated, n 4 3 3 3 5 3 3 3 6 33 37
Evaluable, n
After CVP 3 3 3 3 5 3 3 3 6 32 36
After CBT 3 3 3 3 5 3 3 3 6 32 35
Age at transplantation, 44 45 48 48 43 51 32 45 49.5 46 47
median (range), y (28-46) (39-51) (40-49) (45-55) (36-50) (28-55) (30-48) (36-46) (36-54) (28-55) (27-62)
Time since diagnosis, 5.2 5.9 6.9 5.9 9.2 10.2 7.4 24.1 21.8 7.5 7.1
median (range), mo (5.2-6.4) (5.6-6.1) (3.9-7.3) (4.8-64.2) (5.4-11.0) (7.6-56.3) (5.1-7.8) (10.1-95.1) (7.0-53.4) (3.9-95.1) (4.0-14.3)
Disease stage, n
II 1 1 1 1 2 1 1 0 1 9 17
III 3 2 2 1 2 1 1 1 0 13 20
Metastatic 0 0 0 1 1 1 1 2 5 11 0
*Group A patients received rhTPO on day 5 following CVP chemotherapy. 
†Group B patients received rhTPO on days 5, 7, and 9 following CVP chemotherapy.
‡Group C patients received rhTPO on days 5, 7, and 9 following CVP chemotherapy and on days –14, –11, 0, 2, 4, and 6 relative to CBT
chemotherapy and PBPC transplantation.
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RESULTS
Patient Characteristics
A total of 33 patients were enrolled in the rhTPO treat-
ment groups. All 33 rhTPO-treated patients were evaluable
for treatment safety during the mobilization phase. One
patient in group A developed chemotherapy-related pul-
monary toxicity after receiving CVP and did not undergo
leukapheresis or transplantation; the other 32 rhTPO-
treated patients were evaluable during the transplantation
phase. The control group comprised 37 patients. One
patient in this group did not undergo leukapheresis; the
other 36 patients were evaluable for PBPC mobilization
endpoints. One of these 36 patients did not undergo CBT
treatment, so there were 35 evaluable control patients dur-
ing the transplantation phase.
Patient characteristics are described in Table 1. The
median age of patients in the rhTPO-treated groups was rel-
atively young at 46 years (range, 28-55 years). The median
time from diagnosis of breast cancer to transplantation was
7.5 months (range, 3.9-95.1 months). The greatest propor-
tion of patients had stage III disease. No patient had received
more than 2 prior chemotherapy regimens. The characteris-
tics of the patients in the control group were similar to those
of the patients in the rhTPO-treated groups.
Treatment Administration and Safety
During the mobilization phase, 13 patients received a sin-
gle dose of rhTPO (group A) and 20 patients received 3 doses
of rhTPO (groups B and C). During the transplantation
phase, 6 patients (group C) received 6 additional doses of
rhTPO, 3 prior to infusion of the transplant graft and 3 after-
ward. A total of 104 doses of rhTPO were administered to all
patients entered in this study.
The adverse events experienced by the rhTPO-treated
patients after CVP and CBT were those expected with these
chemotherapeutic regimens. After CVP administration, the
most common adverse events reported were nausea (100%),
vomiting (91%), diarrhea (88%), fever (81%), and headaches
(72%). After CBT administration, the most common adverse
events were esophagitis (87%), diarrhea (84%), fever (81%),
hypokalemia (74%), and nausea (74%). No differences in the
incidence, severity, or type of chemotherapy-related adverse
events were observed among the rhTPO regimens.
During the mobilization phase, 5 patients experienced
adverse effects that were described as possibly related to
rhTPO. These events included catheter thromboses (n = 2),
bone pain (n = 1), rash (n = 1), and anxiety (n = 1). During
the transplantation phase, in which only patients in group C
received rhTPO, events considered possibly related to
rhTPO included fever (n = 4), rash (n = 2), and chills (n = 1).
None of the adverse events that were possibly linked to
rhTPO required discontinuation of rhTPO dosing. No
maximum tolerated dose of rhTPO was reached over the
dose range tested.
PBPC Mobilization
Of the evaluable rhTPO-treated patients, 29 (91%) of 32
achieved a target PBPC graft of 5 × 106 CD34+ cells/kg after
only 1 leukapheresis (Table 2); only 25 (69%) of 36 evaluable
control patients (P = .026) were able to achieve a target graft
with just 1 leukapheresis. The median yield of CD34+
cells/kg per leukapheresis was 26.7 × 106 (range, 3.7-198.0)
for all rhTPO-treated patients compared with 11.5 × 106
(range, 1.4-141.3) in the control group. Because of a substan-
tial degree of variability, the difference between these results
was not statistically significant (P = .09). Although cohort
sizes were small, there was a suggestion of a dose-dependent
increase in the number of CD34+ cells in patients receiving
multiple rhTPO injections (Table 2, group B).
Hematologic Recovery
Patients were monitored for the recovery of neutrophils
(ANC levels of 0.5 × 109/L and 1.0 × 109/L) and platelets
(levels of 20 × 109/L, 50 × 109/L, and 100 × 109/L) after the
mobilizing CVP chemotherapy. The time to recovery of
neutrophils did not differ signiﬁcantly in the rhTPO-treated
Table 2. Leukapheresis and PBPC Harvest*
rhTPO-Treated Patients Control
Group A Group B Group C Overall Patients P
Evaluable, n 3 3 3 3 5 3 3 3 6 32 36
rhTPO dose level, 0.6 1.2 2.4 3.6 0.6 1.2 2.4 3.6 1.2 — — 
µg/kg
Cumulative rhTPO 0.6 1.2 2.4 3.6 1.8 3.6 7.2 10.8 3.6 — — 
dose, µg/kg
No. leukaphereses 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 ND
to collect target (1.0-1.0) (1.0-2.0) (1.0-2.0) (1.0-1.0) (1.0-2.0) (1.0-1.0) (1.0-1.0) (1.0-1.0) (1.0-1.0) (1.0-2.0) (1.0-3.0)
graft, median 
(range)
Patients with target 3 2 2 3 4 3 3 3 6 29 25 .026
graft after 1 leuk- (100) (67) (67) (100) (80) (100) (100) (100) (100) (91) (69)
apheresis, n (%)
No. of CD34+ cells/kg 28.4 24.1 15.7 7.5 9.4 58.0 89.1 135.1 38.4 26.7 11.5 .09
per leukapheresis, (18.5-42.8) (15.4-24.9)(4.5-182.3) (7.4-62.6) (4.8-21.0) (32.4-85.4) (4.3-102.2)(123.3-198.0) (3.7-82.2) (3.7-198.0) (1.4-141.3) 
median (range), ×106
*P values are for comparison of rhTPO-treated groups overall (n = 32) with controls (n = 36). See Table 1 footnotes for descriptions of patient
groups. ND indicates not determined.
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patients compared to the control group (Table 3). Time to
platelet recovery to 20 × 109/L and 50 × 109/L did not differ
significantly between the rhTPO-treated and control
groups. Platelet recovery to 100 × 109/L was more rapid in
the rhTPO-treated group (P = .007), occurring a median of
3.5 days sooner than in the control group.
There were no apparent differences between rhTPO-
treated patients and controls in hematologic recovery after
high-dose CBT chemotherapy and autologous transplanta-
tion of the mobilized PBPCs (Table 4).
Anti-TPO Antibody Testing
Two patients had positive results for the screening
ELISA assay testing for anti-TPO antibodies to full-length
TPO. One patient had positive test results at baseline prior
to receiving TPO and had a platelet count of 155,000. After
receiving 1 dose of TPO, the other patient had a positive
result on what was to have been day –7 prior to receiving
the preparative regimen. This patient did not go on to
receive the transplant because of the development of inter-
stitial pneumonitis from CVP. Within 24 days of recovering
from CVP, the patient’s platelet counts had exceeded 90,000,
and the conﬁrmatory titers were negative. Subsequent test-
ing on both patients was negative and both patients remain
alive with normal platelet counts at the time of this report.
Other than these 2 patients, no other patients were positive
for anti-TPO antibodies. None of the patients had positive
results in the ELISA evaluating antibody formation against
the truncated form of TPO containing the receptor-binding
region. Likewise, there was no indication of positivity in the
functional assays assessing c-mpl receptor blocking or inhi-
bition of HU-3 proliferation. There was also no evidence of
thrombocytopenia attributable to TPO neutralization.
DISCUSSION
Hematopoietic progenitors circulate in low frequency in
the peripheral blood, but their numbers are markedly
increased after chemotherapy and after treatment with the
hematopoietic growth factors G-CSF or GM-CSF [9]. After
high-dose chemotherapy and autologous PBPC transplanta-
tion, hematopoietic recovery correlates with the number of
CD34+ cells infused [24]. The minimum number of pro-
genitor cells needed for transplantation is not precisely
deﬁned, but most centers generally require at least 1 to 2 ×
106/kg CD34+ cells. A target dose of 3 to 5 × 106 CD34+
cells/kg has been recommended to aid in prompt, reliable
hematopoietic recovery [9].
G-CSF alone is commonly used to mobilize blood pro-
genitors for collection. Even at optimal doses and after 4 or
Table 3. Mobilization Phase: Hematologic Recovery after CVP Chemotherapy*
Control Patients Days
rhTPO-Treated Patients Days to Recovery, Median (Range) to Recovery, Median
Group A (n = 12) Group B (n = 14) Group C (n = 6) Overall (n = 32) (Range) (n = 37) P
ANC 0.5 × 109/L 15 (14-17) 14.5 (13-21) 15 (13-18) 15 (13-21) 15 (13-17) NS
ANC 1.0 × 109/L 15 (14-18) 15 (13-22) 15 (13-18) 15 (13-22) 15 (13-19) NS
Platelets 20 × 109/L 15 (12-19) 15.5 (11-21) 15 (12-19) 15 (11-21) 16 (11-24) NS
Platelets 50 × 109/L 18.5 (15-25) 18.5 (14-25) 17.5 (16-22) 18 (14-25) 19 (13-34) NS
Platelets 100 × 109/L 20 (18-32) 20.5 (16-32) 21.5 (19-25) 20.5 (16-32) 24 (17-34) .007
*P values are for comparison of rhTPO-treated groups overall (n = 32) with controls (n = 37). See Table 1 footnotes for descriptions of patient
groups. NS indicates not signiﬁcant.
Table 4. Transplantation Phases: Hematologic Recovery after High-Dose CBT Chemotherapy and PBPC Transplantation*
rhTPO-Treated Patients Control
Group A Group B Group C Overall Patients P
Evaluable, n 3 3 3 3 5 3 3 3 6 32 35
rhTPO dose level, 0.6 1.2 2.4 3.6 0.6 1.2 2.4 3.6 1.2 — — 
µg/kg
Cumulative rhTPO 0.6 1.2 2.4 3.6 1.8 3.6 7.2 10.8 3.6 — — 
dose, µg/kg
Day of ANC recovery 16 15 16 16 16 15 15 14 15.5 15 15 NS
to 0.5 × 109/L, (15-16) (15-16) (14-17) (14-18) (15-16) (14-17) (15-17) (8-15) (14-17) (8-18) (13-16)
median (range)
Day of platelet 15 18 14 15 22 16 16 15 15.5 16 15 NS
recovery to 20 ×109/L, (12-16) (15-18) (14-18) (13-18) (18-27) (15-25) (14-19) (7-15) (13-17) (7-27) (12-21)
median (range)
No. of platelet 3.0 4.0 2.0 3.0 7.0 3.0 3.0 1.0 2.0 3.0 ND ND
transfusion events, (1-5) (3-7) (2-4) (2-4) (3-17) (1-16) (2-8) (1-2) (1-3) (1-17)
median (range)
*P values are for comparison of rhTPO-treated groups overall (n = 32) with controls (n = 35). See Table 1 footnotes for descriptions of patient
groups.
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more leukaphereses, only 2 of every 3 patients reach target
hematopoietic progenitor cell counts, and some patients fail
to achieve the minimum dose necessary for transplantation.
The combination of high-dose chemotherapy and G-CSF is
often used to enhance yields beyond those that can be
achieved with G-CSF alone while providing further cancer
cytoreduction [9].
In this study, we evaluated the safety of rhTPO adminis-
tered according to several doses and schedules and its ability
to enhance chemotherapy- and G-CSF-mediated mobiliza-
tion of PBPCs in patients with advanced breast cancer. The
results showed that administration of rhTPO in this trial
was not associated with overt toxicity. Low-grade adverse
events considered possibly related to rhTPO might just as
likely have been related to chemotherapy or other drugs.
Excessive thrombocytosis was not a concern. The only
thrombotic events occurred at the sites of central venous
catheters. A speciﬁc contribution of rhTPO to these events
could not be excluded but clinically seemed unlikely given
the timing of the events. There was no evidence of neutral-
izing anti-TPO antibody formation. Other studies have
indicated that such antibody formation is a concern, how-
ever, and future studies must continue to evaluate this risk.
rhTPO reduced leukapheresis requirements while
enhancing PBPC cell yields. Significantly more rhTPO-
treated patients achieved a target cell count with only 1 leuk-
apheresis than did control-group patients not receiving
rhTPO. A trend toward higher numbers of PBPCs was
observed when patients given rhTPO were compared with
control patients. The small number of patients evaluated at
each of the dose levels and the variability in PBPC yields
precluded definitive observation of a dose-response effect.
However, rhTPO doses ≥1.2 µg/kg given as multiple infu-
sions seemed to provide more effective PBPC mobilization.
Administration of rhTPO following mobilization chemo-
therapy with CVP was also associated with a significantly
faster recovery of platelet count to ≥100 × 109/L.
Transplantation of rhTPO-mobilized PBPCs was effec-
tive in supporting patients following high-dose chemo-
therapy with CBT. Median time to recovery was ≤16 days
for both neutrophils (ANC ≥0.5 × 109/L) and platelets
(platelet count ≥20 × 109/L). However, these median times
were not different from the 15-day median recovery times
noted in control patients, and the addition of rhTPO (in
group C) before and after high-dose CBT chemotherapy
and PBPC transplantation did not further speed posttrans-
plantation platelet recovery. Although it was hoped that use
of rhTPO-mobilized PBPCs and application of additional
rhTPO to support patients in the transplantation period
would enhance hematologic reconstitution, it is not surpris-
ing that these effects were not observed in the current trial.
Both treated and control patients were generally early in the
course of their breast cancer, had undergone relatively little
prior therapy, and had grafts that were adequate to ensure
rapid recovery of both neutrophils and platelets.
The results of the current study are similar to those of
another study in which G-CSF and rhTPO alone were used
for mobilization [21], in that they show that rhTPO is safe
and effective when used as a PBPC-mobilizing adjunct to
G-CSF. Our trial further demonstrates that rhTPO can
enhance PBPC mobilization when given with both chemo-
therapy and G-CSF. The enhanced mobilization by rhTPO
combined with chemotherapy and G-CSF could provide
several beneﬁts. Reduction in the number of required leuka-
phereses could reduce patient discomfort and inconvenience
while saving money, resources, and staff time, which
increase along with the number of PBPC collection and
storage procedures. Studies have suggested that decreasing
the number of PBPC collections minimizes the risk of
tumor cell contamination in the PBPC products [25-28].
Another beneﬁt is the prospect of greater yields per leuka-
pheresis, which might allow patients to receive multiple
infusions of PBPCs following repeated courses of high-dose
chemotherapy. Finally, rhTPO may provide a special beneﬁt
by enhancing PBPC numbers in heavily pretreated patients
who might otherwise not achieve target yields. Further
studies are warranted, particularly to assess the rhTPO
effect in patients who mobilize poorly with currently avail-
able mobilization regimens.
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